NUT Carcinoma (NC) is most aggressive cancer caused due to the NUTM1/BRD4 alteration which generates BRD4-NUT oncoprotein leads to the inadequate activation of chromatin then its blocks the differentiation1,3. This fusion mediated cancer is symbol of broader pathology called as Chromatin addiction, in this dangerous cell become reliant on non-standard epigenomic landscapes for the ability to survive and spread. Traditional medicine policies have targeted the bromodomain & extra terminal domain (BET) proteins for identifies acetyl-lysine moieties of histones for oncogenic transcription. BET inhibitors (BETi’s) such as JQ1 and its clinical analogues changes the position of BRD4-NUT from the chromatin, it responsible to suppress expression of oncogenes & promote differentiation with only modest or temporary clinical responses, which highlighting the needs for additional therapeutic strategies1-4. Now days, it has become clear that the epigenetic terrain of NC also includes reciprocal dependencies other than abnormal acetylation. Inhibitory chromatin compounds that are the Polycom repressive complex 2 (PRC2) and its enzyme EZH2 have been identified to play a crucial role in tumorigenesis via silencing of tumour suppressor genes6. That means EZH2 is inhibited by haemostat then we clearly see a restoration of the silenced tumour suppressors and produce a synergistic effect with BET inhibition which in turn to reduces proliferation, it promotes differentiation & stop the tumour growth in preclinical NC models7. The other epigenetic modifiers like p300/CBP histone acetyltransferases that's targets on tumoral activity and work by BETi’s8. Then all the results are put forth a model of targeted epigenetic therapy beyond the use of BET inhibitors for NC which promotes the use of combination and multi targeted strategies to get over and minimize epigenetic dependence and resistance. Keywords: Oncogene addiction, NUT Carcinoma, Chromatin addiction, BET inhibition
Wankhade et al. (Sun,) studied this question.